Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler
2 January 2025FeaturesAmericasCarla Ji-Eun Kim & Deborah Sterling

Outlook for 2025: how Trump and the USPTO will affect life sciences IP

Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.
Americas
5 December 2024   As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.
Americas
19 December 2024   The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.

More on this story

Americas
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.
Americas
5 December 2024   As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.
Americas
19 December 2024   The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.

More on this story

Americas
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.
Americas
5 December 2024   As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.
Americas
19 December 2024   The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.